Russian defense firm Kalashnikov enters pharma market with import-substitution gear

Kalashnikov Concern, the Russian defense manufacturer, has announced a joint venture with an unnamed domestic pharmaceutical producer to launch a line of medical products under the QuikMed brand, targeting a tenfold increase in output volumes for the new segment.

The production program comprises two items: fast-dissolving sublingual strips for acute pain management and absorbable surgical hemostatic sponges. Both are positioned as import-substitution products developed without foreign equipment or software, according to the concern.

Product specifications and cost claims

The hemostatic sponges are manufactured from high-purity domestic raw materials. Kalashnikov Concern states their production cost is two to two-and-a-half times lower than that of imported equivalents.

The sublingual strips are designed for moderate to severe pain associated with deep wounds, fractures, oncological conditions and post-operative recovery. The strips dissolve on the oral mucosa; the manufacturer claims the therapeutic effect arrives ninety-five percent faster than with conventional tablets, reaching a speed of action comparable to injections.

Three use scenarios are envisaged: first-aid administration, care during casualty evacuation, and in-patient hospital treatment.

Testing stage and regional deployment

As of the announcement, both product types are undergoing trials and approbation in medical facilities located in regions bordering the zone of the special military operation (SVO). No regulatory registration date or commercial launch timeline was disclosed.

The concern did not provide capital-expenditure figures, revenue targets, margin expectations or financing details for the QuikMed line. The "tenfold increase" reference applies to planned production volumes relative to an unspecified baseline and carries no independent verification.

Strategic context

The move extends Kalashnikov Concern's diversification beyond small arms and guided weapons into civilian medical technology, leveraging its precision-manufacturing base and the state's import-substitution drive. The absence of foreign machinery and software in the process chain is presented as a supply-chain resilience feature.

Independent assessment of the cost advantage, clinical equivalence and scale-up feasibility remains pending. The unnamed pharmaceutical partner's identity, the regulatory pathway for the sublingual formulation, and the funding structure for the volume expansion have not been made public.

Source: This article was adapted from an original Russian-language publication by Pravda. Ru.